Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02

Url canonique :
Url courte ou permalien :

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy

Langue : Anglais

Auteur :

Couverture de l’ouvrage Basics of Chimeric Antigen Receptor (CAR) Immunotherapy

T cell adoptive immunotherapy has been envisioned to cure metastatic malignant cancers. The recent clinical data obtained with the checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy have been especially promising that have generated renewed hope that we may be at the verge of finally curing the cancer. The disease has been devastating families and individuals around the globe. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs as well as CAR-Therapy that has seem unprecedented interest in the immunotherapy field.

  • First book to provide basic understanding of chimeric antigen receptors (CARs) design, production and clinical application protocols
  • Provides unique distinction as the editor has working directly with CARs
  • Discusses the challenges encountered in actual clinical trials and these challenges can be overcome
  • Full chapter dedicated discussing the various challenges expected to encounter in CAR-therapy field
1. An introduction to CAR immunotherapy
2. Components and design of Chimeric Antigen Receptors (CARs)
3. scFv cloning, vectors and CAR production in laboratory for preclinical application
4. Production of CAR-T cells for clinical application
5. Challenges and opportunities to improve CAR-TE cell therapy
Dr. Mumtaz Balkhi brings dual backgrounds in cancer biology and immunotherapeutics to a research program in translational research. With a Ph.D. in Human Biology, he applies molecular biology techniques and utilizes his knowledge of molecular and cellular immunology to develop new gene therapies to improve immunotherapies against cancer. He has more than 20 publications in highly reputable journals including Science and Cell Press Journals. His 2013 publication in Science Signaling Journal featured as Cover Story and his latest publication in Cell Press journal was recently highlighted in Cell Press Crosstalk. Dr. Balkhi hopes to establish a Chimeric Antigen Receptor (CAR) Immunotherapy program. He is trained in this field and had an opportunity to drive and lead projects related to CAR Immunotherapy.

Date de parution :

Ouvrage de 166 p.

15.2x22.9 cm

À paraître, réservez-le dès maintenant

97,13 €

Ajouter au panier

Thème de Basics of Chimeric Antigen Receptor (CAR) Immunotherapy :

En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.